多罗替韦加恩曲他滨与联合抗逆转录病毒疗法在维持艾滋病抑制方面的疗效和安全性对比：SIMPL'HIV试验第144周的结果。

IF 3.8 4区医学 Q2 IMMUNOLOGY

Open Forum Infectious Diseases Pub Date : 2024-10-16 eCollection Date: 2024-11-01 DOI:10.1093/ofid/ofae618

Annalisa Marinosci, Delphine Sculier, Gilles Wandeler, Sabine Yerly, Marcel Stoeckle, Enos Bernasconi, Dominique L Braun, Pietro Vernazza, Matthias Cavassini, Laurent Decosterd, Huldrych F Günthard, Patrick Schmid, Andreas Limacher, Mattia Branca, Alexandra Calmy

{"title":"多罗替韦加恩曲他滨与联合抗逆转录病毒疗法在维持艾滋病抑制方面的疗效和安全性对比：SIMPL'HIV试验第144周的结果。","authors":"Annalisa Marinosci, Delphine Sculier, Gilles Wandeler, Sabine Yerly, Marcel Stoeckle, Enos Bernasconi, Dominique L Braun, Pietro Vernazza, Matthias Cavassini, Laurent Decosterd, Huldrych F Günthard, Patrick Schmid, Andreas Limacher, Mattia Branca, Alexandra Calmy","doi":"10.1093/ofid/ofae618","DOIUrl":null,"url":null,"abstract":"The SIMPL'HIV study investigated whether switching to dolutegravir (DTG) + emtricitabine (FTC) was noninferior to continuing combined antiretroviral therapy for maintaining HIV-1 suppression at 144 weeks. The study demonstrated that viral suppression, CD4 gains, adverse events, quality of life, and patient satisfaction were comparable between groups, confirming DTG + FTC's safety and efficacy for long-term management of HIV-1 infection.","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae618"},"PeriodicalIF":3.8000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540136/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL'HIV Trial.\",\"authors\":\"Annalisa Marinosci, Delphine Sculier, Gilles Wandeler, Sabine Yerly, Marcel Stoeckle, Enos Bernasconi, Dominique L Braun, Pietro Vernazza, Matthias Cavassini, Laurent Decosterd, Huldrych F Günthard, Patrick Schmid, Andreas Limacher, Mattia Branca, Alexandra Calmy\",\"doi\":\"10.1093/ofid/ofae618\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The SIMPL'HIV study investigated whether switching to dolutegravir (DTG) + emtricitabine (FTC) was noninferior to continuing combined antiretroviral therapy for maintaining HIV-1 suppression at 144 weeks. The study demonstrated that viral suppression, CD4 gains, adverse events, quality of life, and patient satisfaction were comparable between groups, confirming DTG + FTC's safety and efficacy for long-term management of HIV-1 infection.\",\"PeriodicalId\":19517,\"journal\":{\"name\":\"Open Forum Infectious Diseases\",\"volume\":\"11 11\",\"pages\":\"ofae618\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-10-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540136/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Forum Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ofid/ofae618\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Forum Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ofid/ofae618","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

SIMPL'HIV研究调查了改用多鲁曲韦 (DTG) + 恩曲他滨 (FTC) 是否比继续采用联合抗逆转录病毒疗法更能维持144周的HIV-1抑制。研究结果表明，两组患者的病毒抑制率、CD4 增量、不良反应、生活质量和患者满意度相当，证实了 DTG + FTC 用于长期治疗 HIV-1 感染的安全性和有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL'HIV Trial.

The SIMPL'HIV study investigated whether switching to dolutegravir (DTG) + emtricitabine (FTC) was noninferior to continuing combined antiretroviral therapy for maintaining HIV-1 suppression at 144 weeks. The study demonstrated that viral suppression, CD4 gains, adverse events, quality of life, and patient satisfaction were comparable between groups, confirming DTG + FTC's safety and efficacy for long-term management of HIV-1 infection.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Open Forum Infectious Diseases Medicine-Neurology (clinical)

CiteScore

6.70

自引率

4.80%

发文量

630

审稿时长

9 weeks

期刊介绍： Open Forum Infectious Diseases provides a global forum for the publication of clinical, translational, and basic research findings in a fully open access, online journal environment. The journal reflects the broad diversity of the field of infectious diseases, and focuses on the intersection of biomedical science and clinical practice, with a particular emphasis on knowledge that holds the potential to improve patient care in populations around the world. Fully peer-reviewed, OFID supports the international community of infectious diseases experts by providing a venue for articles that further the understanding of all aspects of infectious diseases.